StockMarketWire.com - Minster Pharmaceuticals, the AIM quoted drug development company, has announced that The Lancet Neurology, a peer-reviewed journal, has published positive results from a Phase 11 trial of tonabesat in the prevention of migraine with aura.


Story provided by Business Financial Newswire